Reference information

Historical FDA context for magnetic-field devices.

This page keeps the requested historical timeline. Each milestone relates to a particular device category and labelled use.

In a 2022 IEEE lab study, researchers observed changes that they interpreted as a possible increase in the negative surface charge of red blood cells.

Read the study (IEEE, 2022)
Important: This historical context is not a statement that CellVolt™ is FDA approved, cleared or authorised for any condition. It is not medical advice and does not promise an individual outcome.
  1. 1979

    Bone-growth stimulation for non-union fractures

    Historical FDA authorisation for a specific electromagnetic bone-growth device category and a defined fracture indication.

    Source: Cadossi R, Massari L, Racine-Avila J, Aaron RK. Pulsed Electromagnetic Field Stimulation of Bone Healing and Joint Preservation. JAAOS Global Research & Reviews. 2020.

    Open source
  2. 1987

    Postoperative pain and oedema device use

    A historical, device- and indication-specific regulatory milestone described in the PEMF literature.

    Source: Waldorff EI, Zhang N, Ryaby JT. Pulsed Electromagnetic Field Applications: A Corporate Perspective. Journal of Orthopaedic Translation. 2017.

    Open source
  3. 1998

    Muscle stimulation and urinary incontinence devices

    A historical FDA milestone for particular electromagnetic device uses. It is not a general wellness-device approval.

    Source: Waldorff EI, Zhang N, Ryaby JT. Journal of Orthopaedic Translation. 2017.

    Open source
  4. 2004

    Cervical spine fusion support

    FDA authorisation for the named Cervical-Stim device in a defined adjunct spinal-fusion setting.

    Source: FDA PMA P030034, Cervical-Stim Model 505L Cervical Fusion System.

    Open source
  5. 2008

    Transcranial magnetic stimulation

    An FDA milestone for a separate transcranial magnetic stimulation device category and labelled adult indication.

    Source: Cohen SL, Bikson M, Badran BW, George MS. Brain Stimulation. 2022.

    Open source
  6. 2011

    Tumour Treating Fields

    An FDA milestone for a separate Tumour Treating Fields device category and its specific labelled use.

    Source: Rominiyi O, Vanderlinden A, Clenton SJ, et al. British Journal of Cancer. 2021.

    Open source
CV
CellVolt™by Simply Reset

A CellVolt™ wellness licence opportunity with private demonstrations, partner training, and an evidence-led research library.

Stay Updated

Subscribe to receive the latest CellVolt™ research, territory updates, and licence opportunities.

We respect your privacy. Unsubscribe at any time.

© 2026 CellVolt™ by Simply Reset. All rights reserved.